Intrinsiqq
Synlogic Inc. logo

Synlogic Inc. Insider Trading

SYBX

⊜ Compare
Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in May 2022.

Net open-market
$0
0 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
0 / 0
executives and directors
Last open-market buy
May 2022
May 24, 2022

Get an email when SYBX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 29, 2025No plan
    Mary Beth Dooley
    See Remarks below · sold 157 at $1.81
    $284
    1.2% of stake
  • Apr 2, 2025No plan
    Mary Beth Dooley
    See Remarks below · sold 144 at $1.20
    $173
    1.1% of stake
  • Feb 3, 2025No plan
    Mary Beth Dooley
    See Remarks below · sold 2,107 at $1.33
    3K
    14% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SYBX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SYBX

CompareIntrinsic value
MTNBMatinas Biopharma Holdings Inc.
$1.19+4.39%40
XBIOXenetic Biosciences Inc.
$2.01-3.37%40
CPHIChina Pharma Holdings Inc.
$0.59-3.28%15
BFRIBiofrontera Inc.
$0.90+1.55%30
TBPHTheravance Biopharma Inc.
No recent price82
MDGLMadrigal Pharmaceuticals, Inc.
$400.67+1.10%10
ATNMActinium Pharmaceuticals Inc.
$1.41+0.71%30
KPRXKiora Pharmaceuticals Inc.
$1.66-4.05%10

Spot a number that looks wrong? Check it in SYBX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SYBX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.